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Abstract
Background: Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines
contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin
patch (NanopatchTM) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human
papillomavirus (HPV) vaccine (GardasilH) commonly used as a prophylactic vaccine against cervical cancer.
Methodology/Principal Findings: Micro-projection arrays dry-coated with vaccine material (GardasilH) delivered to C57BL/6
mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16
component of the vaccine between 0.4360.084 ng and 3006120 ng (mean 6 SD) were administered to mice at day 0 and
day 14. A dose of 5566.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus
neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16
weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous
patch delivery than with intramuscular delivery with the needle and syringe at this time point.
Conclusions/Significance: Use of dry micro-projection arrays (NanopatchTM) has the potential to overcome the need for a
vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury
and vaccine avoidance due to the fear of the needle especially among children.
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Introduction
Most vaccines are currently delivered by needle and syringe.
However as a vaccine delivery device, the needle and syringe has
many important shortcomings. These include potential transmis-
sion of blood borne diseases through needle-stick injuries [1] and
needle reuse – approximately 30% of injections for the purpose of
vaccination in developing nations are unsafe [2], and that needle-
stick injuries cause more than 500,000 deaths per year [3]. Needle-
phobia and the pain associated with an intramuscular injection are
also downsides – it is estimated that needle phobia is present in at
least 10% [4] of the population, or higher [5]. The muscle is also a
highly inefficient site for vaccination, as it does not have a high
density of antigen presenting cells. In contrast, the skin is an
attractive alternative site for vaccination due to its dense network
of potent antigen presenting cells (APCs) including Langerhans
Cells (LCs) [6], and many sub-sets of dermal dendritic cells (dDCs)
[7]. The close proximity of these cells to the skin surface means it
could be possible to target them in ways which may reduce pain
and potential of transmission of blood borne pathogens. While
cutaneous delivery has great potential, the closest method used
currently in the clinic – intradermal injection – is technically
difficult, necessitating development of advanced targeting methods
as reviewed in [8,9].
In this study a novel skin patch called the NanopatchTM is used to
target these skin immune cells. The NanopatchTM is a micro-
projection array with uniquely dense projection packing (.20,000/
cm2) and short projections (110 mm in length). This needle density
was designed such that delivered vaccine has been co-localized with
50% skin immune cells – in both epidermis and dermis – upon
cutaneous application without relying on diffusion (see Figure 1) [10].
Previous studies with NanopatchTM immunization have utilized
ovalbumin and split influenza vaccine as antigens without addition
of an adjuvant. Crichton et. al [11] demonstrated high antibody
titers after one immunization with under 2 mg via NanopatchTM
using the model antigen ovalbumin in C57BL/6 mice without a
boost using 65 mm long Nanopatch projections. Fernando et. al.
[10] demonstrated induction of protective levels of functional
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antibodies against influenza in mice with 110 mm long Nano-
patchTM projections (same as used in this study) using a split virus,
unadjuvanted trivalent influenza vaccine (Fluvax 2008H); with a
factor of 100 in delivered dose-sparing, compared to the needle
and syringe. In these previous studies, vaccines were delivered
without adjuvant.
In the current study we extend to explore the utility of the
NanopatchTM in delivering an alum adjuvant. This is important,
because many vaccines are adjuvanted – with Alum in the most
widely used [12].
Indeed, until the recent licensure of AS04, alum was the only
adjuvant to be licensed by the FDA [13]. AS04 is alum based, with
the addition of a lipid based toll-like receptor 4 agonist 3-O-
desacyl-49-monophosphoryl lipid A (MPL) [14]. ‘‘Alum’’ is
chemically either aluminum oxyhydroxide, or aluminum hydro-
xyphosphate. For new technologies to take advantage of currently
licensed vaccines, ideally one should work with alum-adjuvanted
vaccines. So far, solid formulation work has been performed with
alum adjuvant for epidermal powder immunization (EPI) with
hepatitis B [15,16,17], and diphtheria and tetanus toxoids [17].
Extensive alum gel coagulation during drying is suspected to
inhibit the release of antigen such that it is not recoverable upon
rehydration [16], and losses of efficacy have been reported after
lyophilization or freezing [18,19,20]. To minimize these losses
without significantly reducing the amount of alum in the total solid
(,1% [18]), rapid freezing is used to prevent freeze concentration
of solutes in combination with glass forming excipients.
However, in our micro-projection coating, a freeze step is not
only more technically demanding, but has the potential to reduce
the mechanical integrity of the coated layer. The coating must be
mechanically strong enough to remain attached on needle
penetration, and differing thermal expansion properties between
the projections and the vaccine may cause cracking or delamina-
tion of coated layers while the device is brought to ambient
temperature.
Air drying of alum containing formulations was investigated in
Maa et.al.[17], and was found to cause extensive coagulation even
in the presence of trehalose, and/or mannitol, and/or dextran. As
current coating protocols are closer to the air drying protocols
described in [17] as opposed to lyophilization or freeze drying, it is
expected that vaccination with micro-projections dry coated with
an alum containing formulation would result in a poor immune
response. In this paper we use the soluble polymer methyl-cellulose
to reduce coagulation of the gel on dehydration, and to aid in
dissolution on rehydration upon application.
Our disease test case for this study is Human Papillomavirus
(HPV) because – aside from the societal importance of the vaccine
– assays to measure virus neutralization are well established.
Antigen structure is important for raising a virus neutralizing
antibody response [19], making the system sensitive to perturba-
tions in antigen structure which may be caused by alum
dehydration during dry coating.
HPV infection is causative in virtually all cases of cervical
cancer – with HPV DNA present in 99.7% of cervical carcinomas
[20]. Vaccination was made possible by modern recombinant
protein expression systems and the discovery that expression of the
L1 major capsid protein alone was sufficient to produce self-
assembling virus like particles (VLPs) [21,22]. The VLP is an
empty viral particle – so it does not contain the viral genome
which codes for the oncogenic proteins which cause malignancy
[23,24,25] in a natural infection.
Commercially available vaccines GardasilH [Merck] and
CervarixH [GlaxoSmithKline] demonstrated excellent prophylac-
tic action in clinical trials, preventing pre-malignancies and
subsequent cancers in almost 100% in the according-to-protocol
analyses [26,27,28]. Both vaccines contain a form of alum
adjuvant. Immunizations are given as three doses over the course
of six months. These vaccines are prophylactic. HPV is the most
common sexually transmitted infection [29], and cumulative
infection incidence over 2 years post first intercourse is
approximately 30%, with condom use not showing significant
protective effect [30]. Immunization must occur before first
intercourse to be fully protective. Many nations now have national
immunization programs targeting 11 and 12-year-old girls. This
has not been without issues. Mass fainting and headaches are
believed to be caused by a needle phobia and mass hysteria [31],
and vaccination without needles may improve vaccine uptake and
acceptance.
Figure 1. The NanopatchTM concept. A two dimensional array of projections localizes dry coated vaccines to layers of the skin rich in immune
cells. Once the vaccine hydrates, it diffuses through the viable epidermis and dermis.
doi:10.1371/journal.pone.0013460.g001
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Long term efficacy of HPV vaccines is important. While
incidence varies with age, the prevalence even in women between
the ages of 40 and 49 is estimated at 25.2% [32], so the potential
for infection continues over a lifetime. Duration of protection is a
significant factor in the cost effectiveness of HPV vaccines [33],
and any second generation vaccines must demonstrate long lasting
protection.
Intra-dermal injection of Canine Oral Papillomavirus (COPV)
L1-glutathione-S-transferase fusion pentamers – similar to HPV
pentamers – has been shown to be protective in beagles at 400 ng/
dog [33]. Suzich, J.A., et al. [34] demonstrated that assembled
COPV-VLP resulted in complete protection at a 50 ng dose level,
and partial protection at 0.125 ng using the intra-dermal route in
beagles.
The HPV VLP is assembled from 72 pentamers of the L1
protein [35,36]. Disassembly of the VLPs can be reversibly
performed in-vitro at high pH, low salt concentration, and with the
addition of reducing agents (for example pH 8.2, 0.166M NaCl
with 2 mM DTT). Dialysis against a pH 6.8 buffer with a salt
concentration of 0.5–1 M results in assembly of the particles [37].
Lenz, P., et al. [38] demonstrates that HPV16L1-VLPs alone but
not their constituent L1-pentamers induce maturation of dendritic
cells in-vitro. Tho¨nes et. al. [39] estimate that immunization with
L1-pentamers also requires 20–40 fold more protein administered
to obtain similar antibody response. Denatured L1 protein does
not give a virus neutralizing antibody response [19], and while dry
formulations can mean longer shelf life at higher temperature, a
poor formulation can cause significant degradation of protein
products. Suitable liquid formulations for HPV-VLP stability have
been defined for both Gardasil [40] and Cervarix [41]. As the
formulation has an impact on the assembly of the VLPs (and
potentially the structure of the capsomeres themselves) and VLPs
are more immunogenic than the capsomeres, formulation is
important for the potency of a dry coated vaccine. Both vaccines a
component of alum adjuvant – Gardasil contain aluminium
hydroxyphosphate. To our knowledge, studies using solid
formulations have not been published for HPV, or HPV adsorbed
to alum.
The NanopatchTM design used in this study utilizes a 58658
array of micro-projections 110 mm high, and 30 mm in base
diameter, with a spacing of 70 mm between projection centers (see
Figure 2). Vaccine is dry coated onto micro-projections as
described in [42], and NanopatchesTM are applied at 2 ms21.
This configuration delivers material into the epidermal and dermal
layers of mouse ear skin with a penetration depth of 42 mm
(SD = 9.9, N = 365), as determined by imaging of fluorescent
tracer in cryo-sectioned mouse ears as described in [11], but with
similar projections to those utilized in [10].
In this paper, we demonstrate dry coating and release of an
alum adjuvanted HPV-VLP vaccine with the NanopatchTM. We
then demonstrate a subsequent immune response which is long
lasting, and neutralizes the virus to levels comparable with
intramuscular injection with the needle and syringe.
Results
Projection morphology of dry coated NanopatchesTM is
suitable for needle penetration
Coated patches were examined by scanning electron microsco-
py (SEM) using secondary electron and backscattered modes
(Figure 2) to investigate the distribution of the coated vaccine
along projections. Secondary electron mode showed the surface
shape of the coated needles, while backscattered electron mode
was used to qualitatively confirm the thickness of the coating due
to differences in the atomic mass of the gold NanopatchTM surface
and the coating. Attempts to dry coat alum adjuvant without
excipient resulted in minimal vaccine coating on needle tips, and
crystallization of the alum adjuvant (Figure S1). Therefore we
added methyl-cellulose to stabilize the vaccine and improve
coating morphology (Figure 2). A significant proportion of the
coating was localized to the tapered portion of the projections.
This can be seen in the secondary electron images by the
difference in morphology before and after coating, and in the
backscattered electron images by the dark signal on projection tips.
In the 800 ng group, some bridging between projections was
observed in certain areas of the NanopatchesTM (indicated by the
arrow in Figure 2b) probably due to the higher concentration of
vaccines than that in other groups.
Vaccine is released from projection tips, and bulk delivery
efficiency is consistent with expectations based on
coating morphology and penetration data
Tenfold serial dilutions of GardasilH were prepared and 14C
labeled Ovalbumin added as a tracer to each sample, coated on
NanopatchesTM, and applied to the ventral earlobe of C57BL/6
mice (N = 5 per dose group) as detailed in Materials and Methods.
A mass balance using the radiolabeled tracer was performed
between the total coated amount, and that which was delivered
into the ear skin, left on the NanopatchTM, or deposited on the
surface of the skin. Efficiency of release was: 19% (SD = 7.5), 34%
(SD = 4.7), 36% (SD = 10), and 27% (SD = 5.2) for 800 ng, 80 ng,
8 ng, and 0.8 ng of coated HPV-16 respectively (see Figure 3).
Delivery percentages were then used to calculate effective doses
by multiplying delivery efficiency by the coated amount. Delivery
amounts were estimated at 300 ng (SD = 120), 55 ng (SD = 6.0),
5.7 ng (SD = 1.6), and 0.43 ng (SD = 0.084) of HPV-16L1.
NanopatchesTM post-application were also visualized with SEM
to determine whether any coating solution still remained on
projections. Low molecular mass material was detected on the
base in some instances, but seldom on projection tips (Figure S3)
NanopatchTM vaccination elicits long lasting virus
neutralizing immune response, comparable with
intramuscular
NanopatchTM doses were divided over each ear (i.e. one patch
per ear), and administered at day 0 and again at day 14. Sera were
collected at day 28 and day 112 after vaccination to examine the
immediate response, and the longer term persistence of antibodies
post vaccination. Sera were assayed for ability to neutralize the
HPV virus with the pseudovirion-based neutralization assay
(PBNA) (Figure 4). A non-inferiority analysis was used (Materials
and Methods) similar to previous Human Papillomavirus immu-
nization comparison studies [43].
At day 28 post-immunization, titers in the 3006120 ng and
5566.0 ng dose NanopatchTM groups were statistically non-
inferior to all intramuscular doses (p,0.001) with geometric mean
titer (GMT) of 30500 and 26000 respectively (Figure 4). In each of
the 5.761.6 ng and 0.4360.084 ng dose level NanopatchTM
groups, two mice did not seroconvert.
Neutralizing antibodies were titered at day 112 post-immuni-
zation (Figure 4) to establish long-term efficacy. At day 112 post-
immunization, all NanopatchTM groups showed 100% sero-
conversion. At day 112, all NanopatchTM doses were statistically
non-inferior to all intramuscular doses (p,0.05).
When comparing the response at day 112 and day 28 within
each group (Figure 4), the day 112 titer did not meet non-
inferiority criteria against the day 28 titer in both the 100 ng and
Micro-Projection Vaccination
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Figure 2. Representative scanning electron micrographs examining projection coating morphology in both secondary and
backscattered electron modes. Secondary electron images show the surface morphology while backscattered electron images show composition
– with low atomic mass elements giving low signal – i.e. coated area appears dark in comparison with the uncoated NanopatchTM. Micro-projections
are coated at b) 800 ng, c) 80 ng, d) 8 ng and e) 0.8 ng of HPV-16 protein per patch. While some bridging is occurring in the 800 ng group (panel b –
white arrow), coating is seen on the tapered portion of projections in all dose groups.
doi:10.1371/journal.pone.0013460.g002
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1 ng intramuscular groups (ratio of titres: 100 ng 90% CI (0.40,
1.2), and 1 ng 90% CI (0.39,1.2)). In contrast, within group
NanopatchTM titer comparisons showed titres at day 112 were
non-inferior in all cases, and superior at the 0.4360.084 ng dose
level, with the day 112 titer being 1.2–5.8 times higher than the
day 28 titer (p,0.05) at the same dose.
Discussion
This paper demonstrates effective coating and release of an
alum containing vaccine GardasilH from a novel micro-projection
array patch (NanopatchTM) designed to deliver vaccine directly to
about 50% of the abundant skin antigen presenting cells [10], for
efficient induction of a virus neutralizing antibody response.
Release efficiency varied between dose groups. It is predicted
that this is primarily dependant on the coating morphology. This is
supported by our theoretical delivery expectations (Figure S2).
Our predicted releases (Figure S2) as compared with measured
release were most accurate within the lowest dose groups. We
over-predicted the release in the highest dose groups. This
discrepancy is likely to be due to bridging between projections
and excessive coating on the base of NanopatchesTM (Figure 2b)
leading to wastage of coating solution. Since coating on the base
and bridging projections were not accounted for in calculations,
Figure 3. Proportion of 14C radio-labeled tracer protein coated onto the NanopatchTM which is released into the ear skin upon
application. Release was determined by mass balance, and varied between coated amounts with an average of 19%, 34%, 36%, and 27% for the
formulations used for 800 ng, 80 ng, 8 ng, and 0.8 ng of coated HPV-16 per NanopatchTM.
doi:10.1371/journal.pone.0013460.g003
Figure 4. Pseudovirion neutralization assay titers at day 28 and day 112 after immunizations at day 0 and boost at day 14.
NanopatchTM doses were 300 ng (SD= 120), 55 ng (SD=6.0), 5.7 ng (SD=1.6) and 0.43 ng (SD=0.084). Intramuscular doses were 10 mg, 1 mg,
100 ng, 10 ng, and 1 ng. At day 28, NanopatchTM 300 ng and 55 ng dose groups have reached comparable virus neutralizing titers to all
intramuscular injection groups (p,0.05). By day 112, all NanopatchTM doses have reached comparable neutralizing titres against all intramuscular
injection groups (p,0.05). Replicates are staggered in x axis to aid in visualization. Unimmunized plotted at a dose of 0.05 ng due to log scale.
doi:10.1371/journal.pone.0013460.g004
Micro-Projection Vaccination
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where these amounts are significant, it would result in an
overestimate of delivered amount as the theoretical calculations
were only based upon coating solution on the projections. This
bridging will likely be alleviated by the addition of a surfactant in
later formulations. These data, and the post application images
demonstrate that the release from the projections is complete, and
thus with advances in coating technology to isolate coating solely
to portions of the projections which penetrate skin, complete
release 100% efficiency is possible with these formulations.
Fast release is likely to aid in ensuring consistent vaccine dose is
delivered, as it is easier to ensure compliance with the
immunization protocol. An observation period of 15–20 minutes
following a standard intramuscular immunization is generally
recommended as most anaphylactic shock will occur within this
period [44]. Release of the dry coated vaccine from the
NanopatchTM occurred within five minutes – thereby easily
meeting observation period guidelines.
To demonstrate that virus neutralizing antibodies were raised,
serum was screened by the Pseudovirion-Based Neutralization
Assay (PBNA) – considered the ‘‘gold standard’’ in the WHO
guidelines for HPV vaccines [45,46]. This assay measures the
effectiveness of antibodies or other compounds in blocking the
entry of the HPV virus into 293TT cells [47]. This is significant, as
protection is believed to be a result of antibody mediated virus
neutralization [48,49]. The method also removes the bias of using
the same material for both immunization and immunological
assay which occurs when ELISA is used. Assay signal is only
generated by intact pseudovirions that mimic the native virus, thus
any immune response raised against contaminants or denatured
protein will not impact the results of the neutralization assay.
NanopatchTM immunization with 0.4360.084 ng of HPV-16
resulted in virus neutralizing response at day 112 after vaccination.
This implies that the dry coated L1 protein maintains some native
virus-like structure. We speculate that some degree of disassembly
of VLP into pentamers may have occurred. This assertion is based
on our similar studies using viral vectors (unpublished data).
Owing to the increased immunogenicity of VLPs in comparison
with pentamers, if disassembly into pentamers is currently
occurring during dry-coating, a great increase in activity is likely
through reformulation to further preserve VLP structure.
While early results showed only 50% sero-conversion in the
5.761.6 ng and 0.4360.084 ng NanopatchTM groups, advantages
become clearer at the terminal bleed when all mice have sero-
converted. At the lower doses intramuscular began to falter, with
the titers of two mice dropping below the detection limit. It is
possible that NanopatchTM immunization, with alum containing
vaccines, has slower release kinetics as compared with intramus-
cular administration – owing to the different administration site
and a greater depot effect from dehydrated alum. While extremely
low doses of HPV-VLP appear immunogenic intramuscularly in
mice, doses for humans in the approved vaccines are in the 20–
40 mg range per subtype. Slow release kinetics may favorably alter
immunological outcomes and assist in achieving optimal activation
of APCs without the need to physically apply more doses. Further
work is required to investigate this.
Previous studies of intradermal immunization with COPV [33,34]
utilized an ELISA assay so a direct comparison with our results is not
possible. Suzich et al [34] studied the intradermal delivery of
assembled COPV-VLPs and obtained partial protection at sub-
nanogram dose level. By comparison, a later study by Yuan, et. al.
[33] with intradermal administration of COPV-L1-GST fusion
protein (unable to assemble into VLPs) showed no detectable response
by ELISA below a 400 ng dose. This work focused on assembly
incompetent pentamers as an inexpensive alternative to VLPs. In both
instances, partial protection was noted against challenge even when
antibodies were not detected. NanopatchTM immunization with split
virion influenza vaccine gives superior dose reduction against
intramuscular [10] as compared with what has been demonstrated
in intradermal administration [50]. If disassembly of HPV-VLPs is
occurring in our NanopatchTM dry coating, the closest effective dose
comparison is with the work of Yuan et al. This would suggest that
NanopatchTM immunization may give increased immunogenicity in a
direct comparison with intradermal administration (and thus
presumably intramuscular administration) of L1-pentamers. Howev-
er, as the currently licensed vaccines are VLP based, reformulation to
preserve VLP integrity will be the focus of future work.
Our release assays measure the proportion of coating which is
released into the skin – they do not measure what proportion of
antigen is effectively released from the alum, nor its conformation
on release. If the alum gel is coagulated, in accordance with
previous studies [17], antigen may not escape the collapsed alum
matrix – thus reducing the effective dose. This effect may in fact
negate any adjuvant benefits the alum otherwise provides, though
further study is required to determine the extent to which the alum
matrix impairs release, and its impact. Future work will investigate
protein structure and coagulation of the alum as well as excipients
to reduce it. As HPV-L1-VLPs are highly immunogenic even
without adjuvant, formulations without alum will also be
investigated. We speculate that with enhanced formulations,
NanopatchTM immunization may eventually mean lower doses
of alum adjuvanted VLP can be used to elicit a lasting immune
response in humans.
Future work will focus on improving dose sparing in
NanopatchTM immunization, and investigating thermostability.
To this end, dry coated VLP integrity, exploring unadjuvanted
VLPs and improving formulations will be explored.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the
University of Queensland animal ethics regulations.
NanopatchTM Fabrication
NanopatchesTM were fabricated by Deep Reactive Ion Etching
according to patent [51] in the Rutherford Appleton Laboratory,
Oxford, UK. NanopatchesTM were sputter coated with gold to a
thickness of 100 nm. Uniform morphology was confirmed by
Scanning Electron Microscopy (SEM) on a Philips XL30. Samples
were tilted at 45u to confirm appropriate projection profile.
NanopatchTM Coating
GardasilH (Merck, USA) was centrifuged at 5000 g for 15
minutes to pellet the alum with the adsorbed virus like particles.
The supernatant was removed and the pellet re-suspended in
methylcellulose to a final concentration of 10 mg/mL methylcel-
lulose, and 100 ng/mL of HPV-16-VLP. Ten-fold serial dilutions
were prepared in 10 mg/mL methylcellulose to formulate different
doses. MethocelH 60 HG - Methyl-cellulose (cat # 646555) was
purchased from Sigma Aldrich (Castle Hill, NSW, Australia).
NanopatchesTM with 110 mm long needles were coated by
pipetting 8 mL of coating solution onto the surface and dry coating
via nitrogen jet as previously described [42]. Appropriate coating
morphology was confirmed by SEM.
NanopatchTM Immunization
Four groups (N = 5) of female C57BL/6 mice at 6 wks old were
anesthetized with KetamilH and XylasilH. Mice were then patched
Micro-Projection Vaccination
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once in each ear on the ventral side using a spring application
device to apply the patch at 2.0 ms21 - a velocity found to give
maximal needle penetration without damaging tissue (data not
shown). Doses stated in this paper refer to total HPV-16 dose for
each immunization distributed over two NanopatchesTM, and
mice were immunized at day 0 and boosted at day 14. Patches
were held in situ for 5 minutes. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Health and
Medical Research Council (Australia). The protocol was approved
by the Committee on the Ethics of Animal Experiments of the
University of Queensland (Permit Number AIBN/020/10 (NF)).
All efforts were made to minimize suffering.
Intramuscular injections
GardasilH doses were concentrated by centrifugation at 5000 g
for 15 minutes. Excess supernatant was removed and pellet was re-
suspended in the appropriate amount of supernatant to give an
HPV-16 VLP concentration of 0.2 mg/mL. Four 10-fold serial
dilutions were prepared into the excess supernatant.
Five groups (N = 5) of C57BL/6 mice at 6 wks old were
immunized intramuscularly at day 0 and boosted at day 14 with
25 uL delivered approximately 2 mm into each caudal muscle of
the hind leg with each group receiving 10 mg, 1 mg, 100 ng, 10 ng,
or 1 ng of HPV-16 per mouse per immunization.
Control Application
Topical control: One group (N = 5) of C57BL/6 mice at 6 wks
old were anesthetized with ketamil and xylasil. Mice were
restrained with ventral ear surface flat, and 125 mL of GardasilH
(containing 10 mg of HPV-16) was applied topically for five
minutes.
Fluvax immunized control: One group (N = 5) of C57BL/6
mice at 6 wks old were anesthetized with KetamilH and XylasilH,
and immunized intramuscularly with 6 mg of Fluvax 2008H (CSL
Ltd., Melbourne, Australia) in a volume of 30 mL.
Unimmunized control: One group (N = 5) of C57BL/6 mice at
6 wks were anesthetized with KetamilH and XylasilH and sacrificed
immediately upon cessation of reflexes by cardiac puncture.
Sera collection
Blood samples were obtained at day 28 and 112 after
vaccinations by retro-orbital bleeds, and serum separated. Sera
were stored at 220uC until analysis.
Scanning Electron Microscopy (SEM)
Samples were examined in secondary electron and back
scattered electron modes in a Philips XL30. Samples were tilted
to 45u to enable visualization of the needles, and imaged at an
accelerating voltage of 20 kV.
Predicted delivery image analysis
The canny edge detection method was used in MATLABH
2010a (The MathsworksTM) to generate the outline of a silhouette
of projection shapes on both coated and released NanopatchesTM.
Silhouettes were filled in and checked manually as binary images,
with coated projections at a grey level of 0 and released projections
at a grey level of 255, and images were overlaid to generate a
binary image of expected coating shape. For each projection, a
region-of-interest was created based on the proportion of the
projection expected to penetrate skin from fluorescent dye studies
[11] and ratios of amount of coating on each projection tip as
compared with the whole projection were taken.
Radiometric delivery analysis
1.5 ml vials of GardasilH were concentrated to 330 mL via
centrifugation, and tenfold serial dilutions were made in saline –
final alum concentrations – 1 mg/mL, 100 ng/mL, 10 ng/mL,
1 ng/mL, and 0.1 ng/mL all in a volume of 300 mL. 80 nCi of 14C
Radio-labeled ovalbumin tracer (American Radiolabeled Chem-
icals Cat# ARC 0431) was added to each vial, and incubated for
one hour at room temperature. Binding efficiency of tracer to the
alum within 30 minutes was 95%. The mixtures were then
centrifuged at 5000 g for 15 minutes, the supernatants collected in
vials for scintillation counting, and the pellets re-suspended in
10 mg/mL methylcellulose to a final volume of 54 mL. Nano-
patchesTM were coated with the radio-labeled formulation as
described above, and applied to mouse ears (N = 5/dose) as
described for NanopatchTM immunization. Ear surfaces were
swabbed to remove vaccine left on the surface of the ear and not
delivered into the cell layers below. Ears were excised and
solubilized in Soluene (Perkin Elmer) for 4 hours at 60uC. Swabs,
ears and used NanopatchesTM were placed in scintillation vials
and 10 mL of Hionic Fluor (Perkin Elmer) was added to each vial.
Samples were counted for two minutes per sample in a liquid
scintillation counter.
Pseudovirion-Based Neutralization Assay (PBNA)
Pseudovirion based Neutralization assay was performed as
previously described [52]. Briefly 100 mL of 293TT (generously
provided by John Schiller, NIH, USA) cells were plated at 36105
cells/mL in 96-well plates and allowed to attach. Serum was
diluted in three-fold serial dilutions from 1:100 to 1:1968300,
mixed with type 16 pseudovirions expressing secreted alkaline
phosphatase (SEAP) (plasmids p16shell and pYSEAP generously
provided by John Schiller, NIH, USA), and pre-incubated on ice
for 1 hour before addition to cell layers. In plate controls were five
wells of cells without pseudovirion applied, and five wells of cells
with pseudovirion applied at the same concentration as in wells
incubated with serum. Plates were incubated for 3 days at 37uC,
and SEAP expression was quantified using the colorimetric
approach. Plates were read at 405 nm absorbance, and data was
normalized between cells only and pseudovirion only wells. Log
transformed data was fitted with the four parameter dose-response
model (GraphPadTM Prism v5.03 ). Neutralization titer was
calculated as the theoretical dilution of serum which gives 50%
reduction in SEAP expression (EC50 from the model). Non sero-
converted samples were assigned an arbitrary titer of 1.
Non-inferiority analysis
Two-sided 90% confidence intervals (CI) of the anti-HPV-16
titer ratios (NanopatchTM divided by comparison group) were
calculated on the log10 transformation of the ratio between titers
under comparison using the Fieller’s theorem [53]. If the lower tail
of the CI was greater than 0.5, non-inferiority was concluded. If
the lower tail of the CI was greater than 1.0, superiority was
concluded.
Supporting Information
Figure S1 Coating without excipient. Representative secondary
electron (left - S.E) and backscattered electron (right - B) SEM
images of a NanopatchTM coated without adding the polymer
methylcellulose. Crystallization of the coating is evident, and
backscattered electron imaging confirms that coating is localized
towards the base of the micro-projections and the NanopatchTM.
Found at: doi:10.1371/journal.pone.0013460.s001 (0.57 MB
TIF)
Micro-Projection Vaccination
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13460
Figure S2 Theoretical delivered amounts compared with
measured. Theoretical (marked with asterisks) and actual propor-
tion (solid bars) of 14C radio-labeled tracer protein coated onto the
NanopatchTM which is released into the ear skin upon
application. Theoretical released amount was determined by
image analysis of coated NanopatchesTM, and varied between
coated amounts with estimates of 35%, 48%, 36%, and 36% for
the formulations used for 800 ng, 80 ng, 8 ng and 0.8 ng of coated
HPV-16 per NanopatchTM.
Found at: doi:10.1371/journal.pone.0013460.s002 (2.02 MB TIF)
Figure S3 NanopatchesTM after five minute application to
mouse ear skin. Secondary and backscattered electron scanning
electron micrographs of NanopatchesTM after 5 minute applica-
tion to the ear skin. Backscattered electron images show the atomic
mass of compounds imaged - thus darker areas represent lower
atomic number elements - such as the coating solution. It can be
seen that coating is no longer on projections as in figure 3. Low
atomic mass material on the base of projections as seen in panels d
and b may be either coating solution or biological matter post-
application.
Found at: doi:10.1371/journal.pone.0013460.s003 (6.53 MB TIF)
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